BPRG Bioprogress

RNS Number:6062C
BioProgress PLC
22 August 2007


For Immediate Release                                            22  August 2007

                                BioProgress plc

                                 Notice of EGM

London, UK, 22 August 2007: BioProgress plc ('BioProgress', the 'Company' or 
'Group') (AIM: BPRG), the specialty pharma and healthcare company announces that
it has posted to its shareholders a notice convening an Extraordinary General
Meeting ('EGM').

The purpose of this EGM is to approve the name change of the Company from
BioProgress Plc to Meldex International Plc and to update shareholders on the
current progress of the Group.

Reason behind name change

The Company's business model has changed fundamentally over the past two years
from an industrial based technology "push" business to a market led product
focused sales and marketing concern. The Group is therefore entirely different
to that originally named 'BioProgress' and it is consequently appropriate to
alter the Company's title to reflect that change.

The initial catalyst of change, post the H2 2005 restructuring programme, was
the acquisition of the speciality prescription medicine business Dexo S.A. This
brought product, regulatory infrastructure and a sales and marketing capability
to the Group. This function was added to in the UK, Italy and the US throughout
2006. At the same time, a new formulation and development capability was
established providing pipeline growth through new products, product enhancements
and line extensions for the prescription and over-the-counter (OTC) health care
markets, using the companies unique enabling systems.   In addition, these
systems are utilised for third party partner product programmes.

More recently the Group acquired the Melbrosin group of companies, strengthening
its product and geographical presence in the rapidly growing healthcare OTC
markets.

The corporate trading brands Dexo and Melbrosin are now the market face of the
Group. They act as both a marker of the Company's progress through product
offerings and as a means of identifying market trends which help determine
future product development. Considering the importance of these brands to the
Group, the Board consider it appropriate to combine the Company's trading brands
under a new umbrella brand for the Group. In addition, reflecting the Company's
international operations, the Board consider it vital to reinforce the
multinational nature of the Company.

The Directors believe that 'Meldex International Plc' represents a brand name
and image which more closely resembles the business and direction of the Group.

Recommendation

The Board of Directors unanimously recommends that Shareholders vote in favour
of the results being proposed at the EGM. The Board of Directors believe the
resolution being proposed in the best interest of Shareholders as a whole.

Notice of EGM

The EGM will be held at Clifford Chance, 10 Upper Bank Street, London, E14 5JJ,
on Thursday 13 September at 10am for the purpose of considering and if thought
fit, passing the following resolution, which will be proposed as a Special
Resolution:

"That the registered name of the Company be changed to Meldex International Plc"

Expected timetable of principal events

                                                                            2007

Latest time and date for receipt of forms of proxy           10 am, 11 September

Extraordinary General Meeting                                10 am, 13 September


For further information:

BioProgress Plc                                            + 44 (0) 20 7098 9881
Richard Trevillion, CEO
Steve Martin, CDO
Hiral Patel, CFO

Buchanan Communications                                    + 44 (0) 20 7466 5000
Rebecca Skye Dietrich
Mark Court


About BioProgress

BioProgress plc is an innovative specialty pharmaceutical and healthcare
business based around its platform technologies in polymer and film systems.
Listed on London's AIM in May 2003, The company has over 80 patents granted or
in application within 24 patent families and has product development agreements
and strategic alliances with several global companies. As a virtually integrated
business, BioProgress has acquired sales and marketing resources within Europe
and the US as a launch mechanism for its own pharmaceutical products. The
business continues to develop innovative delivery mechanisms using its XGEL(TM)
polymer technology. For further information please go to www.bioprogress.com

Forward-Looking Information

The Ordinary Shares of BioProgress plc are registered under the US Securities
and Exchange Act of 1934.  To the extent that this announcement contains certain
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995, this paragraph applies.  These statements are
based on management's current expectations and are subject to uncertainty and
changes in circumstances.  Actual results may vary materially from the
expectations contained in the forward-looking statements.  The forward-looking
statements in this release include statements addressing future financial and
operating results and the timing and benefits of the reorganisation.  Detailed
information about factors pertinent to the business of the company that could
cause actual results to differ is set forth in the Company"s filings with the
Securities and Exchange Commission.  The Company is under no obligation to (and
expressly disclaim any such obligation to) update or alter its forward-looking
statements whether as a result of new information, future events or otherwise.
This announcement is for information only and does not constitute an offer or
invitation to acquire or dispose of any securities or investment advice.  The
distribution of the announcement and/or issue of securities in certain
jurisdictions may be restricted by law.  Persons into whose possession this
announcement comes are required to inform themselves about and to observe such
restrictions.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

NOEPUUAWRUPMPWG

Bioprogress (LSE:BPRG)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024

Bioprogress (LSE:BPRG)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024